AbbVie reaches agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ELAHERE® in Platinum-Resistant Ovarian Cancer

AbbVie is pleased to announce that negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) have successfully been completed for ELAHERE® (mirvetuximab soravtansine for injection), and that a Letter of Intent (LOI) has been signed by both parties.